131685-53-5

Basic information

• Product Name: (R)-(-)-4-BENZYL-3-PROPIONYL-2-OXAZOLIDINONE
• Synonyms: (R)-4-BENZYL-3-PROPIONYL-2-OXAZOLIDINONE;N-PROPIONYL-(4R)-BENZYL-2-OXAZOLIDINONE;N-3-PROPIONYL-(4R)-BENZYL-2-OXAZOLIDINONE;(R)-(-)-4-Benzyl-3-propiomyl-2-oxazolidinone;(4R)-4-benzyl-3-propanoyl-1,3-oxazolidin-2-one;(-)-4-Benzyl-3-propionyl-2-oxazolidinone;(4R)-4-Benzyl-3-propionyl-1,3-oxazolidin-2-one;(4R)-4-Benzyl-3-propionyloxazolidin-2-one
• CAS NO: 131685-53-5
• Molecular Formula: C₁₃H₁₅NO₃
• Molecular Weight: 233.26
• Product Categories: Oxazolidinone;chiral;Asymmetric Synthesis;Chiral Building Blocks;Glycidyl Compounds, etc. (Chiral);Synthetic Organic Chemistry;Peptide;Asymmetric Synthesis;Chiral Auxiliaries;Oxazolidinone Derivatives;Aromatics;Chiral Reagents;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 131685-53-5.mol
• Article Data: 73

Chemical Properties

• Melting Point: 45 °C
• Boiling Point: 396.639 °C at 760 mmHg
• Flash Point: 193.681 °C
• Appearance: white to light yellow crystal powder
• Density: 1.206 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: -103 ° (C=1, EtOH)
• Storage Temp.: Inert atmosphere,Room Temperature
• Solubility: Chloroform, Ethanol
• PKA: -2.35±0.40(Predicted)
• CAS DataBase Reference: (R)-(-)-4-BENZYL-3-PROPIONYL-2-OXAZOLIDINONE(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-(-)-4-BENZYL-3-PROPIONYL-2-OXAZOLIDINONE(131685-53-5)
• EPA Substance Registry System: (R)-(-)-4-BENZYL-3-PROPIONYL-2-OXAZOLIDINONE(131685-53-5)

Safety Data

• Hazard Codes: Xi,Xn
• Statements: 20/21/22-36/37/38
• Safety Statements: 26-36-24/25
• WGK Germany: 3
• Hazardous Substances Data: 131685-53-5(Hazardous Substances Data)

Usage

Chemical Properties

white to light yellow crystal powde

Uses

Different sources of media describe the Uses of 131685-53-5 differently. You can refer to the following data:
1. (R)-(-)-4-BENZYL-3-PROPIONYL-2-OXAZOLIDINONE is a oxazolidinone derivative used in the preparation of anisomycin analogues as activators of the JNK/SAPK1 and p38/SAPK2 pathways.
2. (R)-(?)-4-Benzyl-3-propionyl-2-oxazolidinone can be used as a building block for the preparation of methyl 3-[(S)-3-((R)-4-benzyl-2-oxooxazolidin-3-yl)-2-methyl-3-oxopropyl]benzoate by treating with strong base followed by the addition of methyl 3-bromomethyl benzoate.

General Description

(R)-(?)-4-Benzyl-3-propionyl-2-oxazolidinone is used as a building block in organic synthesis for the preparation of oxazolidinone derivatives.

InChI:InChI=1/C13H15NO3/c1-2-12(15)14-11(9-17-13(14)16)8-10-6-4-3-5-7-10/h3-7,11H,2,8-9H2,1H3/t11-/m1/s1

Upstream product

• 90719-32-7 (S)-4-Benzyl-2-oxazolidinone 
• 123-62-6 propionic acid anhydride 
• 352438-07-4 ⁽⁴⁵⁾-3-propionyl-4-benzyl-2-oxazolidinone 
• 1239664-46-0 (R)-4-benzyl-3-[(S)-2-(tert-butyldimethylsilyloxymethyl)butanoyl]oxazolidin-2-one 
• 907593-86-6 (R)-4-benzyl-3-[(S)-2-(hydroxymethyl)butanoyl]oxazolidin-2-one 
• 645386-89-6 (R)-4-benzyl-3-((S)-2-(benzyloxymethyl)butanoyl)-1,3-oxazolidin-2-one 
• 1501971-59-0 (2R,3S,4R)-1-((R)-4-benzyl-2-oxooxazolidin-3-yl)-2,4-dimethyl-1-oxohexan-3-yl-4-methylbenzenesulfonate 
• 1501971-58-9 (4R)-4-benzyl-3-((2R,3S,4R)-3-hydroxy-2,4-dimethylhexanoyl)oxazolidin-2-one 
• 474828-48-3 (R)-4-benzyl-3-((R)-2-methylbutanoyl) oxazolidin-2-one 
• 111292-87-6 (R)-3-(1-butyryl)-4-benzyloxazolidine-2-one 
• 40217-17-2 (R)-4-(phenylmethyl)-2-oxazolidinone 
• 4122-52-5 1-(1H-imidazol-1-yl)propan-1-one 
• 802294-64-0 propionic acid 
• 90719-32-7 4-benzyl-2-oxazolidinone 

Downstream Products

• 138166-61-7 (4R,2'R)-<3'-13C>-(2'-methyl-3'-oxopentanoyl)-4-benzyl-2-oxazolidinone 
• 116996-56-6 (4S)-4-benzyl-3-[(2R)-2-methylpent-4-enoyl]oxazolidin-2-one 
• 171189-79-0 (S)-4-Benzyl-3-((2S,3R)-7-benzyloxy-3-hydroxy-2-methyl-heptanoyl)-oxazolidin-2-one 
• 177767-29-2 (3(2S,4R)4R)-3-(2,4-dimethyloctanoyl)-4-benzyl-2-oxazolidinone 
• 177607-84-0 (3(2S,4S)4R)-3-(2,4-dimethyloctanoyl)-4-benzyl-2-oxazolidinone 
• 183960-51-2 (4R)-4-benzyl-3-((2S)-4-bromo-2-methyl-1-oxo-4-pentenyl)-2-oxazolidinone 
• 150004-36-7 (R)-4-Benzyl-3-((Z)-(2R,3R)-4-chloro-3-hydroxy-2-methyl-hex-4-enoyl)-oxazolidin-2-one 
• 185903-63-3 (R)-4-Benzyl-3-((2R,3S)-3-hydroxy-2,6-dimethyl-hept-6-enoyl)-oxazolidin-2-one 
• 183610-32-4 (4S,2'S,3'R)-3-(3'-hydroxy-2'-methyl-7'-octynoyl)-4-(phenylmethyl)-2-oxazolidinone 
• 197227-61-5 (S)-4-benzyl-3-[(2S,3R)-4-cyclopent-3-enyl-3-hydroxy-2-methylbutanoyl]-oxazolidin-2-one 
• 943856-58-4 (S)-4-benzyl-3-((S)-2-methylpent-4-enoyl)oxazolidin-2-one 
• 211504-69-7 di-n-butylboron enolate of (S)-4-benzyl-N-propionyl-2-oxazolidinone 
• 251319-55-8 (R)-4-Benzyl-3-((E)-(2R,3S)-6-benzyloxy-3-hydroxy-2-methyl-hex-4-enoyl)-oxazolidin-2-one 

Relevant articles and documents

SUBSTITUTED TETRAHYDROFURANS AS MODULATORS OF SODIUM CHANNELS

Compounds, and pharmaceutically acceptable salts thereof, useful as inhibitors of sodium channels are provided. Also provided are pharmaceutical compositions comprising the compounds or pharmaceutically acceptable salts and methods of using the compounds, pharmaceutically acceptable salts, and pharmaceutical compositions in the treatment of various disorders, including pain.

Synthesis and Bioactivity of a Macrocidin B Stereoisomer

A stereoisomer of macrocidin B, a presumed metabolite of the fungus Phoma macrostoma, was synthesized in 18 steps and 2.7% yield from protected l-tyrosine that was N-β-ketoacylated with a fully functionalized octanoyl Meldrum's acid. Dieckmann condensation gave a 3-acyltetramic acid, which was macrocyclized via Williamson etherification between the phenol and epi-bromohydrin termini. This macrocidin B stereoisomer showed a weaker herbicidal effect than macrocidin A and no similar inhibitory effect on biofilms of Staphylococcus aureus.

Novel chiral stationary phases based on 3,5-dimethyl phenylcarbamoylated β-cyclodextrin combining cinchona alkaloid moiety

Novel chiral selectors based on 3,5-dimethyl phenylcarbamoylated β-cyclodextrin connecting quinine (QN) or quinidine (QD) moiety were synthesized and immobilized on silica gel. Their chromatographic performances were investigated by comparing to the 3,5-dimethyl phenylcarbamoylated β-cyclodextrin (β-CD) chiral stationary phase (CSP) and 9-O-(tert-butylcarbamoyl)-QN-based CSP (QN-AX). Fmoc-protected amino acids, chiral drug cloprostenol (which has been successfully employed in veterinary medicine), and neutral chiral analytes were evaluated on CSPs, and the results showed that the novel CSPs characterized as both enantioseparation capabilities of CD-based CSP and QN/QD-based CSPs have broader application range than β-CD-based CSP or QN/QD-based CSPs. It was found that QN/QD moieties play a dominant role in the overall enantioseparation process of Fmoc-amino acids accompanied by the synergistic effect of β-CD moiety, which lead to the different enantioseparation of β-CD-QN-based CSP and β-CD-QD-based CSP. Furthermore, new CSPs retain extraordinary enantioseparation of cyclodextrin-based CSP for some neutral analytes on normal phase and even exhibit better enantioseparation than the corresponding β-CD-based CSP for certain samples.